将氨甲酰化生物学转化为肾脏疾病的精准医学
本综述整合生物化学、流行病学与转化研究,阐述蛋白质氨甲酰化由尿素衍生的氰酸盐驱动,是慢性肾脏病(CKD)中连接氮质血症与全身病理的核心机制。CKD患者氨甲酰化水平与死亡、心血管事件、CKD进展及糖化血红蛋白A1c等生物标志物相关,并探讨了饮食或透析干预降低氨甲酰化负荷及精准医学应用的前景。
要点
- CKD是研究过量氨甲酰化全身后果的典型人类模型。
- 氨甲酰化水平与CKD患者死亡、心血管事件及CKD进展相关。
- 氨甲酰化标志物有望用于靶向饮食或透析干预及血糖表型细化。
核心结论
- 蛋白质氨甲酰化是连接氮质血症与多系统临床病理的核心机制,具有作为预后生物标志物和治疗靶点的潜力。
研究设计与样本
- 综述整合生物化学、流行病学和转化肾脏病学研究证据。
主要发现
- 机制研究显示氨甲酰化影响血管生物学、脂质处理、细胞外基质重塑和免疫功能。
- CKD患者氨甲酰化水平与死亡、心血管事件、CKD进展相关,并与糖化血红蛋白A1c等生物标志物存在交互作用。
临床怎么用
- 可考虑使用氨甲酰化标志物指导饮食或透析干预以降低氨甲酰化负荷。
- 可利用氨甲酰化细化血糖表型。
局限性
- 氨甲酰化的因果性与关联性程度尚未明确。
- 尿素衍生与其他氨甲酰化通路的相对重要性未知。
- 氨甲酰化作为预后标志物或治疗靶点的最佳定位尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Protein carbamylation is a nonenzymatic post-translational protein modification driven by urea-derived cyanate and its reactive form isocyanic acid. Because CKD is characterized in part by sustained urea retention and prolonged protein exposure to cyanate, it represents the prototypical human model of the systemic consequences of excess carbamylation. Advances in analytical chemistry and translational nephrology research have reshaped our understanding of carbamylation, transforming it from a biochemical curiosity into a central mechanism linking azotemia to clinical pathology across multiple systems, including cardiovascular, renal, hematologic, and immune pathways. Mechanistic studies demonstrate effects on vascular biology, lipid handling, extracellular matrix remodeling, and immune function while clinically, carbamylation levels in people with CKD are associated with mortality, cardiovascular events, CKD progression, and interaction with biomarkers such as glycated hemoglobin A1c. Promising applications include using carbamylation markers to target dietary or dialysis-based interventions that can lower carbamylation burden and using carbamylation to refine glycemic phenotyping. Despite these advances, major questions remain: the extent to which carbamylation is causal rather than associative; the relative importance of urea-derived versus other carbamylation pathways; and whether carbamylation is best positioned as a prognostic biomarker, a therapeutic target, or both. This review integrates biochemical, epidemiologic, and translational insights to clarify carbamylation's clinical relevance in CKD and outlines emerging opportunities for biomarker development, targeted interventions, and precision medicine approaches that may soon bring carbamylation biology into clinical practice.
引用
- Awwad A, Tang M, Kalim S, et al. Translating Carbamylation Biology into Precision Medicine for Kidney Disease. Clin J Am Soc Nephrol. 2026. PMID: 41842960. doi:10.2215/CJN.0000001061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。